小弟投資股票以來睹得最大的股票: 藥明生物
"The leads on WuXi Bio’s HK$3.9bn ($510.4m) float are guiding investors to the top of its HK$18.6-HK$20.6 marketing range and plan to close books a day earlier, following a blockbuster response."
"The heavily oversubscribed Hong Kong IPO by Wuxi Biologics, is underscoring a promising outlook for biotech companies in Asia."
"首先，藥明生物2016年業績有爆發性增長。其次，從行業角度考慮，接下來的10年甚至20年都是中國生物醫藥自主創新產業的黃金發展期。尤其在大分子這個細分領域，國內現在能與藥明生物比肩的實在太少了" - From 雪球一位行業專家
